Fabienne Thompson

From Random Screening of Chemical Libraries to the Optimization of FPP-Competitive Inhibitors of Farnesyltransferase

P. Vrignaud, M. Bissery, J. Riou, 2001 .

Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.

J. Nicolas, C. Lengauer, L. Vincent, 2012, Journal of medicinal chemistry.

Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.

Jean-Pierre Marquette, Magali Mathieu, Thomas Bertrand, 2014, Journal of medicinal chemistry.

Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.

Paul Ferrari, Patrick Mailliet, Hervé Minoux, 2011, Journal of medicinal chemistry.

SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Joon Sang Lee, C. García-echeverría, L. Debussche, 2020, Molecular Cancer Therapeutics.

MOLECULAR CANCER THERAPEUTICS | SMALL MOLECULE THERAPEUTICS SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Joon Sang Lee, L. Debussche, M. Levit, 2020 .

Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.

M. Mathieu, C. García-echeverría, M. Levit, 2019, Journal of medicinal chemistry.

Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors.

J. Nicolas, C. Lengauer, L. Vincent, 2012, Bioorganic & medicinal chemistry letters.